INTRODUCTION: There are dozens of drugs in development for AD with billions of dollars invested. Despite the massive investment in AD drugs and a burgeoning pipeline, there have been more setbacks and failures than treatment successes. Areas covered: The classes of drugs that have failed to date include the monoclonal antibodies, the gamma secretase inhibitors,…
Expert Opinion on Investigational Drugs Template
Write in a clean editor, then format for Expert Opinion on Investigational Drugs in one click — DocuGuru applies the official Taylor & Francis template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the Expert Opinion on Investigational Drugs format
Expert Opinion on Investigational Drugs is a peer-reviewed journal published by Taylor & Francis, covering Monoclonal and Polyclonal Antibodies Research, Diabetes Treatment and Management, Asthma and respiratory diseases.
| Publisher | Taylor & Francis |
|---|---|
| Reference style | Author–year (Chicago, T&F) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Expert Opinion on Investigational Drugs 12 (3): 45–58.
Formats any DOI in Expert Opinion on Investigational Drugs style. No sign-up. |
| Publishes research in | Monoclonal and Polyclonal Antibodies Research Diabetes Treatment and Management Asthma and respiratory diseases Lipoproteins and Cardiovascular Health HIV/AIDS drug development and treatment |
| ISSN | 1354-3784 |
| Citation impact (2-yr) | 4.35 |
| h-index | 132 |
| i10-index | 2,914 |
| Total citations | 135,973 |
| Top institutions publishing here | Weatherford College |
| Journal website | informahealthcare.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in Expert Opinion on Investigational Drugs per year
Citation impact of Expert Opinion on Investigational Drugs by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in Expert Opinion on Investigational Drugs
Malignant gliomas such as glioblastoma multiforme (GBM) present some of the greatest challenges in the management of cancer patients worldwide, despite notable recent achievements in oncology. Even with aggressive surgical resections using state-of-the-art preoperative and intraoperative neuroimaging, along with recent advances in radiotherapy and chemotherapy, the prognosis for GBM patients remains dismal: median survival after…
A major session at this annual gathering of the cancer researchers from around the globe dealt with the current state of immunotherapy for cancer. Immunotherapy is a form of cancer treatment that enhances its scientific promise and legitimacy with each passing year. As a result, this topic has become one of the most highly attended…
BACKGROUND: The p38 mitogen-activated protein kinase (MAPK) is activated by various pro-inflammatory and stressful stimuli. Mounting evidence suggests that the p38 MAPK signaling cascade is involved in various biological responses other than inflammation such as cell proliferation, differentiation, apoptosis and invasion, suggesting that the p38 MAPK can serve as a potential therapeutic target for the…
Cancer treatment by conventional chemotherapy is hindered by toxic side effects and the frequent development of multi-drug resistance by cancer cells. Cationic antimicrobial peptides (CAPs) are a promising new class of natural-source drugs that may avoid the shortcomings of conventional chemotherapy because certain CAPs exhibit selective cytotoxicity against a broad spectrum of human cancer cells,…